Table 4.
NAC treatment effect on CBC measurements in PLL mice
| Treatments | NAC | Control | Statistics |
|---|---|---|---|
| n | 17 | 17 | |
| WBCs (×109/l) | 6.7 ± 0.6 | 5.6 ± 0.6 | P < 0.1645 |
| Neutrophils (×109/l) | 0.8 ± 0.1 | 0.9 ± 0.1 | P < 0.5456 |
| Lymphocytes (×109/l) | 5.4 ± 0.5 | 4.3 ± 0.5 | P < 0.1350 |
| Monocytes (×109/l) | 0.53 ± 0.04 | 0.31 ± 0.04 | P < 0.0007 |
| RBCs (×1012/l) | 11.3 ± 0.3 | 11.1 ± 0.3 | P < 0.6701 |
| Haemoglobin (g/dl) | 13.2 ± 0.3 | 13.0 ± 0.3 | P < 0.7358 |
| Haematocrit (%) | 43.2 ± 1.1 | 42.5 ± 1.1 | P < 0.6125 |
| MCV (fL) | 38.4 ± 0.6 | 38.2 ± 0.6 | P < 0.8574 |
| RDW (%) | 19.4 ± 0.3 | 18.7 ± 0.3 | P < 0.1236 |
| Platelets (×109/l) | 441 ± 35 | 381 ± 35 | P < 0.2468 |
| MPV (fL) | 3.49 ± 0.04 | 3.49 ± 0.04 | P < 0.9264 |
NAC, N-acetylcysteine; CBC, complete blood count; PLL, Peromyscus leucopus linville; MCV, Mean corpuscular volume; MPV, mean platelet volume; RDW, RBC distribution width.